profit from every $100 of sales.
$0$100
Forte Biosciences
We have no price for Forte Biosciences since 28 August 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$76.99+0.00% today
+404.2% since Oct 10, 25
1-year low $10.301-year high $76.99
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Forte Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$69.4 million of profit last year.
SalesProfit
Forte Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Forte Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Forte Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -14 | -32 | -37 | -71 | |
| -14 | -32 | -37 | -71 | |
| -14 | -31 | -35 | -69 | |
| -20.00 | -24.92 | -12.17 | -4.71 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 42 | 39 | 62 | 83 |
| Cash | 41 | 12 | 22 | 77 |
| Total debt | – | – | – | – |
| Total liabilities | 3 | 4 | 9 | 22 |
| 39 | 35 | 52 | 61 | |
| 1 | 1 | 3 | 15 | |
| -28.3% | -72.7% | -55.1% | -91.5% | |
| -35.8% | -89.1% | -67.6% | -113.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -29 | -31 | -51 | |
| – | 0 | 0 | 0 | |
| -8 | -29 | -31 | -51 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 4 | 3 | 3 | 6 |
Valuation
- –
- –
- –
- 92.5×
- –
- –
- –
- -3.1%
- -4.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -176.6%
- -71.7%
- -106.2%
- -112.8%
- -176.6%
- –
Growth
- –
- –
- −65.7%
- –
- +302.9%
Financial health
- -0.8×
- 0.00
- 0.0%
- –
- 2.75
- 2.75
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 872
Bottom 25%of 986
What analysts expect
- Average price target
- $65.00
- Range
- $65.00 – $65.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -1.24 | -1.16 | −6.9% |
| Mar 31, 2026 | -1.45 | -1.42 | −2.1% |
| Nov 14, 2025 | -0.99 | -1.04 | +4.8% |
| Aug 14, 2025 | -0.96 | -1.21 | +20.7% |
| May 15, 2025 | -1.37 | -0.89 | −53.9% |
| Mar 24, 2025 | -2.45 | -4.55 | +46.2% |
| Nov 14, 2024 | -4.54 | -6.75 | +32.7% |
| Aug 14, 2024 | -6.75 | -4.00 | −68.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
38No pass
Philip Fisher
38No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
28No pass
Questions about Forte Biosciences
Is Forte Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Forte Biosciences AI analysis
What does Forte Biosciences do?
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas. It is in Biotechnology.
Does Forte Biosciences pay a dividend?
No. Forte Biosciences does not pay a dividend at the moment.
Is Forte Biosciences stock halal?
Yes. Forte Biosciences passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
Who are Forte Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Forte Biosciences's.
Prices: daily closes to Aug 28, 2026. Fundamentals: company reports via invest-like data.